Epidemiology of Celiac Disease

Alberto Rubio-Tapia, Jonas F. Ludvigsson, Joseph A Murray

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Celiac disease (CD) is characterized by changes in duodenal and small bowel mucosa that are caused by gluten intolerance. These changes include an increase in intra-epithelial lymphocytes, partial or complete villous atrophy, and hypoplasia of the small bowel architecture. CD usually responds to a gluten-free diet (GFD). In epidemiologic studies CD is often diagnosed serologically with positive anti-enomysium and/or anti-tissue transglutaminase antibodies. CD is found in most populations but is commonest in those of Northern European origin with a prevalence of approximately 1%. There is a strong genetic susceptibility with almost universal association with HLA class II DQ2 or DQ8 haplotypes. Classically CD presents with diarrhea and malabsorption but it is increasingly recognized that the presentation can be atypical with vague abdominal complaints, fatigue, arthralgia, or abnormal laboratory tests such as iron deficiency anemia. Patients with undiagnosed CD have a lower quality of life than the general population and possibly an increased all-cause mortality. It is therefore important for the clinician to have a low threshold for screening for CD with serology. Further studies are needed to better define the risk of undiagnosed CD and whether a GFD ameliorates this risk. Studies evaluating the impact and cost-effectiveness of population screening for CD are also required. This edition first published 2014

Original languageEnglish (US)
Title of host publicationGI Epidemiology: Diseases and Clinical Methodology: Second Edition
PublisherWiley Blackwell
Pages185-195
Number of pages11
ISBN (Electronic)9781118727072
ISBN (Print)9780470672570
DOIs
StatePublished - Jan 13 2014

Fingerprint

Celiac Disease
Epidemiology
Gluten-Free Diet
Population
Iron-Deficiency Anemias
Glutens
Arthralgia
Serology
Genetic Predisposition to Disease
Haplotypes
Atrophy
Cost-Benefit Analysis
Fatigue
Epidemiologic Studies
Diarrhea
Mucous Membrane
Quality of Life
Lymphocytes
Mortality
Antibodies

Keywords

  • Celiac
  • Coeliac
  • Duodenum
  • Epidemiology
  • Gluten
  • Inflammation
  • Prevalence
  • Prevention
  • Quality of life
  • Small intestine

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Rubio-Tapia, A., Ludvigsson, J. F., & Murray, J. A. (2014). Epidemiology of Celiac Disease. In GI Epidemiology: Diseases and Clinical Methodology: Second Edition (pp. 185-195). Wiley Blackwell. https://doi.org/10.1002/9781118727072.ch17

Epidemiology of Celiac Disease. / Rubio-Tapia, Alberto; Ludvigsson, Jonas F.; Murray, Joseph A.

GI Epidemiology: Diseases and Clinical Methodology: Second Edition. Wiley Blackwell, 2014. p. 185-195.

Research output: Chapter in Book/Report/Conference proceedingChapter

Rubio-Tapia, A, Ludvigsson, JF & Murray, JA 2014, Epidemiology of Celiac Disease. in GI Epidemiology: Diseases and Clinical Methodology: Second Edition. Wiley Blackwell, pp. 185-195. https://doi.org/10.1002/9781118727072.ch17
Rubio-Tapia A, Ludvigsson JF, Murray JA. Epidemiology of Celiac Disease. In GI Epidemiology: Diseases and Clinical Methodology: Second Edition. Wiley Blackwell. 2014. p. 185-195 https://doi.org/10.1002/9781118727072.ch17
Rubio-Tapia, Alberto ; Ludvigsson, Jonas F. ; Murray, Joseph A. / Epidemiology of Celiac Disease. GI Epidemiology: Diseases and Clinical Methodology: Second Edition. Wiley Blackwell, 2014. pp. 185-195
@inbook{99c6d5c174454de099c862409b3087d8,
title = "Epidemiology of Celiac Disease",
abstract = "Celiac disease (CD) is characterized by changes in duodenal and small bowel mucosa that are caused by gluten intolerance. These changes include an increase in intra-epithelial lymphocytes, partial or complete villous atrophy, and hypoplasia of the small bowel architecture. CD usually responds to a gluten-free diet (GFD). In epidemiologic studies CD is often diagnosed serologically with positive anti-enomysium and/or anti-tissue transglutaminase antibodies. CD is found in most populations but is commonest in those of Northern European origin with a prevalence of approximately 1{\%}. There is a strong genetic susceptibility with almost universal association with HLA class II DQ2 or DQ8 haplotypes. Classically CD presents with diarrhea and malabsorption but it is increasingly recognized that the presentation can be atypical with vague abdominal complaints, fatigue, arthralgia, or abnormal laboratory tests such as iron deficiency anemia. Patients with undiagnosed CD have a lower quality of life than the general population and possibly an increased all-cause mortality. It is therefore important for the clinician to have a low threshold for screening for CD with serology. Further studies are needed to better define the risk of undiagnosed CD and whether a GFD ameliorates this risk. Studies evaluating the impact and cost-effectiveness of population screening for CD are also required. This edition first published 2014",
keywords = "Celiac, Coeliac, Duodenum, Epidemiology, Gluten, Inflammation, Prevalence, Prevention, Quality of life, Small intestine",
author = "Alberto Rubio-Tapia and Ludvigsson, {Jonas F.} and Murray, {Joseph A}",
year = "2014",
month = "1",
day = "13",
doi = "10.1002/9781118727072.ch17",
language = "English (US)",
isbn = "9780470672570",
pages = "185--195",
booktitle = "GI Epidemiology: Diseases and Clinical Methodology: Second Edition",
publisher = "Wiley Blackwell",

}

TY - CHAP

T1 - Epidemiology of Celiac Disease

AU - Rubio-Tapia, Alberto

AU - Ludvigsson, Jonas F.

AU - Murray, Joseph A

PY - 2014/1/13

Y1 - 2014/1/13

N2 - Celiac disease (CD) is characterized by changes in duodenal and small bowel mucosa that are caused by gluten intolerance. These changes include an increase in intra-epithelial lymphocytes, partial or complete villous atrophy, and hypoplasia of the small bowel architecture. CD usually responds to a gluten-free diet (GFD). In epidemiologic studies CD is often diagnosed serologically with positive anti-enomysium and/or anti-tissue transglutaminase antibodies. CD is found in most populations but is commonest in those of Northern European origin with a prevalence of approximately 1%. There is a strong genetic susceptibility with almost universal association with HLA class II DQ2 or DQ8 haplotypes. Classically CD presents with diarrhea and malabsorption but it is increasingly recognized that the presentation can be atypical with vague abdominal complaints, fatigue, arthralgia, or abnormal laboratory tests such as iron deficiency anemia. Patients with undiagnosed CD have a lower quality of life than the general population and possibly an increased all-cause mortality. It is therefore important for the clinician to have a low threshold for screening for CD with serology. Further studies are needed to better define the risk of undiagnosed CD and whether a GFD ameliorates this risk. Studies evaluating the impact and cost-effectiveness of population screening for CD are also required. This edition first published 2014

AB - Celiac disease (CD) is characterized by changes in duodenal and small bowel mucosa that are caused by gluten intolerance. These changes include an increase in intra-epithelial lymphocytes, partial or complete villous atrophy, and hypoplasia of the small bowel architecture. CD usually responds to a gluten-free diet (GFD). In epidemiologic studies CD is often diagnosed serologically with positive anti-enomysium and/or anti-tissue transglutaminase antibodies. CD is found in most populations but is commonest in those of Northern European origin with a prevalence of approximately 1%. There is a strong genetic susceptibility with almost universal association with HLA class II DQ2 or DQ8 haplotypes. Classically CD presents with diarrhea and malabsorption but it is increasingly recognized that the presentation can be atypical with vague abdominal complaints, fatigue, arthralgia, or abnormal laboratory tests such as iron deficiency anemia. Patients with undiagnosed CD have a lower quality of life than the general population and possibly an increased all-cause mortality. It is therefore important for the clinician to have a low threshold for screening for CD with serology. Further studies are needed to better define the risk of undiagnosed CD and whether a GFD ameliorates this risk. Studies evaluating the impact and cost-effectiveness of population screening for CD are also required. This edition first published 2014

KW - Celiac

KW - Coeliac

KW - Duodenum

KW - Epidemiology

KW - Gluten

KW - Inflammation

KW - Prevalence

KW - Prevention

KW - Quality of life

KW - Small intestine

UR - http://www.scopus.com/inward/record.url?scp=84976407565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976407565&partnerID=8YFLogxK

U2 - 10.1002/9781118727072.ch17

DO - 10.1002/9781118727072.ch17

M3 - Chapter

SN - 9780470672570

SP - 185

EP - 195

BT - GI Epidemiology: Diseases and Clinical Methodology: Second Edition

PB - Wiley Blackwell

ER -